{"id":"NCT02752074","sponsor":"Incyte Corporation","briefTitle":"A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-21","primaryCompletion":"2018-01-08","completion":"2019-08-16","firstPosted":"2016-04-26","resultsPosted":"2019-05-15","lastUpdate":"2025-08-24"},"enrollment":706,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"pembrolizumab + epacadostat","otherNames":[]},{"type":"DRUG","name":"pembrolizumab + placebo","otherNames":[]}],"arms":[{"label":"Pembrolizumab + Epacadostat","type":"EXPERIMENTAL"},{"label":"Pembrolizumab + Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"Assessed every 9 weeks for duration of study participation which is estimated to be 24 months","effectByArm":[{"arm":"Pembrolizumab + Epacadostat","deltaMin":4.7,"sd":null},{"arm":"Pembrolizumab + Placebo","deltaMin":4.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.51711"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":129,"countries":["United States","Australia","Belgium","Canada","Chile","Denmark","France","Germany","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Russia","South Africa","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["31221619"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":353},"commonTop":["Fatigue","Diarrhoea","Nausea","Pruritus","Rash"]}}